Oramed Pharmaceuticals (ORMP) Assets Average (2011 - 2026)

Oramed Pharmaceuticals has reported Assets Average for 16 years, with the latest figure at $249.9 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 65.02% year-over-year to $249.9 million; the trailing twelve-month figure through Mar 2026 stood at $249.9 million (up 65.02% YoY), and the FY2025 full-year result was $193.1 million, up 2.74% from the prior year.
• Assets Average for Q1 2026 stood at $249.9 million, up from $225.7 million in the prior quarter.
• The five-year high for Assets Average was $249.9 million in Q1 2026, with the low at $151.4 million in Q1 2025.
• Historically, Assets Average has averaged $183.7 million across 5 years, with a median of $174.7 million in 2024.
• Annual changes were most pronounced in 2024 — Assets Average retreated 29.04% — and 2026, when it surged 65.02%.
• Oramed Pharmaceuticals' Assets Average stood at $163.0 million in 2022, then jumped by 38.45% to $225.7 million in 2023, then dropped by 29.04% to $160.2 million in 2024, then surged by 40.89% to $225.7 million in 2025, then gained by 10.71% to $249.9 million in 2026.
• The last three Assets Average figures came in at $249.9 million (Q1 2026), $225.7 million (Q4 2025), and $191.1 million (Q3 2025), per Business Quant data.